NEW YORK ( TheStreet) -- Shares of Cell Therapeutics (Nasdaq: CTIC) were gapping down Thursday morning with an open price 15.3% lower than Wednesday's closing price. The stock closed at $1.96 Wednesday and opened today's trading at $1.66. The average volume for Cell has been 2.3 million shares per day over the past 30 days. Cell has a market cap of $333.5 million and is part of the health care sector and drugs industry. Shares are down 10.5% year to date as of the close of trading on Wednesday. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. TheStreet Ratings rates Cell as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins. You can view the full Cell Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.
More from Markets
Stocks Fall as Weak China Growth Returns Focus to Fate of Trade Talks
Stocks decline after China posted its weakest quarterly economic growth rate in nearly three decades, returning investors' attention to the ongoing trade talks between Washington and Beijing.
Share a Coke With Jim? Cramer on Coca-Cola's Earnings, Cloud Kings and Brexit
Jim Cramer breaks down what investors need to know about Coca Cola's earnings, the cloud Kings and why investors need to pay attention to Brexit.
American Express Beats Third-Quarter Estimates as Card Fees Set Record
Record-setting card fees help the credit card giant beat Wall Street's third-quarter earnings expectations.